ropeginterferon alfa-2b in patients with pre-fibrotic primary mf & dipss low/intermediate-1 risk mf
Published 1 year ago • 264 plays • Length 4:31Download video MP4
Download video MP3
Similar videos
-
2:40
safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis
-
1:56
5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
-
3:02
pilot study of ropeginterferon in early myelofibrosis
-
0:56
rop-et: a phase iii non-randomized study of ropeginterferon alfa-2b in patients with et
-
1:49
current and future therapies for pv: ropeginterferon alfa-2b
-
5:47
efficacy of ropeginterferon in mf
-
3:00
ropeginterferon alpha-2b as an effective treatment against pv
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
12:08
oncotrol bone biopsy needle tutorial
-
1:44
flowsaver blood return system
-
2:46
【pharmaessentia】bio asia–taiwan 2022
-
1:24
exceed-et: ropeginterferon alfa-2b in adults with essential thrombocythemia
-
1:29
ropeginterferon alfa-2b for polycythemia vera: impacts and considerations
-
3:15
updates on ropeginterferon in pv
-
1:28
surpass et: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia
-
6:55
bone defect analysis - imalytics preclinical application demo
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:16
ropeginterferon vs standard therapy for polycythemia vera
-
1:35
proud-pv/continuation-pv studies: benefits of ropeg ifn alfa-2b for the treatment of pv
-
1:41
updates on ropeginterferon in mpns
-
2:06
clinical updates on the use of ropeginterferon for polycythemia vera
-
6:00
horizontal ridge augmentation using rhbmp-2 for implant placement